David Liposarcoma Research Initiative
Liposarcomas originate from precursors of fat cells are one of 250 types of sarcoma and are relatively rare, but they have few effective treatments. This Atlas is a subset of a larger, multi-PI David Liposarcoma Research Initiative from the Dana-Farber Cancer Institute, which is led by DFCI Investigator George Demetri. The David Liposarcoma Research Initiative aims to transform the treatment of this rare, underfunded, and understudied disease. As part of this effort, the Laboratory of Systems Pharmacology (LSP) is collecting highly multiplexed images of liposarcomas before and after treatment.
Principal Investigators
- George Demetri, MD, Professor of Medicine, Harvard Medical School
- Sandro Santagata, MD PhD, Associate Professor of Pathology, Brigham and Women’s Hospital and Harvard Medical School
- Peter Sorger, PhD, Professor of Systems Biology, Harvard Medical School
Introduction to Liposarcoma
Multiplexed Imaging of Cell-States and Spatial Organization in Liposarcoma
Click to enlarge
Talk given by Shannon Coy, M.D. (Brigham and Women’s Hospital) for the 2024 David Liposarcoma Research Symposium.
Publications
Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft Tissue Sarcomas: Clinical Outcomes and Biological Correlates
Haddox CL, Nathenson MJ, Mazzola E, Lin JR, Baginska J, Nau A, Weirather JL, Choy E, Marino-Enriquez A, Morgan JA, Cote GM, Merriam P, Wagner AJ, Sorger PK, Santagata S, George S. (2024).
Clinical Cancer Research https://doi.org/10.1158/1078-0432.CCR-23-2250